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Abstract 
BACKGROUND: Dried blood spot (DBS) sampling is a blood collection tool that uses a finger 
prick to obtain a blood drop on a dried blood spot card. It can be used for therapeutic drug 
monitoring, a method that uses blood drug concentrations to optimize individual treatment. DBS 
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aim of this study was to evaluate the quality of drie  blood spots from tuberculosis patients all 
around the world based on quality indicators in a structured assessment procedure.  
METHODS: Total 464 DBS cards were obtained from four countries: Bangladesh, Belarus, 
Indonesia and Paraguay. The quality of the DBS cards was assessed using a checklist consisting 
of 19 questions divided into four categories: the int grity of the DBS materials, appropriate 
drying time, blood volume and blood spot collection.  
RESULTS: After examination, 859 of 1856 (46 %) blood spots did not comply with present 
quality criteria. In 625 cases (34%), this was due to incorrect blood spot collection. The DBS 
cards from Bangladesh, Indonesia and Paraguay seemed to b  affected by air humidity, causing 
the blood spots not to dry appropriately. 
CONCLUSION: New tools to help obtain blood spots of sufficient quality are necessary as well 
as environmental specific recommendations in order to determine plasma-concentrations 
correctly. Additionally, 3% of the DBS cards were rejected because the integrity of the materials 
suggesting that the quality of plastic zip lock bags currently used to protect the DBS cards 
against contamination and humidity may not be sufficient. 
KEYWORDS: Dried Blood Spots (DBS), tuberculosis (TB), quality, therapeutic drug 








Tuberculosis (TB) is a disease that continues to affect people all around the world. In 2017, 6.4 
million new TB cases were reported.1 Bangladesh and Indonesia combined made up 19% of all 
incident TB cases in 2017.1 Drug-susceptible TB is treated with the first-line anti-TB drugs 
isoniazid, rifampicin, pyrazinamide and ethambutol for two months, followed by isoniazid and 
rifampicin for another four months, leading to successful outcomes in 82% of the cases.1,2 To 
optimize TB treatment in patients responding poorly to standard treatment or with risk factors for 
low drug exposure, therapeutic drug monitoring (TDM) can be performed.3 TDM was recently 
recommended in the TB treatment guidelines of the ATS/CDC/IDSA.4 One of the barriers to 
introduce TDM at a large scale is the stability of plasma or serum samples. This can be overcome 
by implementing dried blood spot (DBS) sampling.5 This procedure uses a single drop of blood 
on special absorbent paper to determine the blood drug concentration. DBS has several other 
advantages, such as easy sample collection and shipment through regular mail, which saves costs 
for shipment on dry ice.6 Also, DBS minimizes the biohazard risk due to the us of dried 
samples, which is a major advantage in countries with a high prevalence of human 
immunodeficiency virus (HIV) co-infection.5,6 The small sample volume of 20-100 µl blood is a 
major advantage compared to the 4-10 ml of venous blood collected for conventional blood 
sampling, making this method suitable for children,7 but also for those who oppose to large 
volume venous blood sampling.  
There are two DBS sampling methods: The first method involves letting the blood drop fall 
directly within the pre-marked circle, followed by partial spot analysis. The second method 
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followed by full-spot analysis.6 The first method is often preferred as it can be performed by 
untrained personnel but inaccurate sampling may influe ce analytical results.7  
Although preliminary results are promising, some hurdles still need to be overcome before DBS 
sampling can be implemented in TB programs.8 Laboratories need to clinically validate DBS 
methods comparing venous samples to fingerprick samples to be able to offer a range of assays. 
Hematocrit has shown to be of influence on analytical results and should therefore be included 
during clinical validation.9-11 Health care workers have to get familiar with the sampling 
procedure and pitfalls need to be examined.  
The aim of this study was to assess, using a structured checklist, whether dried blood spots of 
sufficient quality can be obtained with limited training and to give recommendations on how to 
improve the quality of DBS samples.  
 
Materials and Methods 
DATA SETS 
Feasibility of DBS was evaluated in 5 different settings: International Centre for Diarrhoeal 
Disease Research in Bangladesh, Grodno Oblast Clinical Centre "Ftiziatria" in Belarus, Lung 
Hospital Respira, Yogyakarta in Indonesia, Instituto Nacional de Enfermedades Respiratorias y 
del Ambiente Juan Max Bohener in Paraguay and Indigenous Hospital of Limpio in Paraguay. 
Healthcare workers received DBS packages containing: a  instruction form, a patient letter, a 
request form, Whatman FTA DMPK-C DBS cards, plastic ziplock bags to store and ship the 
cards, desiccant sachets to be included in the ziplock bag for storage and shipment and lancets to 
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workers only received written instructions and an instruction video in English.12,13 DBS samples 
were collected from TB patients receiving standard first-line anti-TB treatment. Ethical clearance 
was obtained at all sites and patients gave written nformed consent.  
 
VALIDITY OF THE DRIED BLOOD SPOT CARDS 
DBS cards, containing four blood spots, were scored upon four categories: integrity of the DBS 
materials, appropriate drying time, blood volume and blood spot collection. The aspects that a 
DBS card has to comply with for an accurate analysis were based on the ‘Blood collection and 
handling – Dried Blood Spots’ manual of the World Health Organization (WHO).14,15 For the 
category integrity of the DBS materials, the plastic zip lock bags were checked if the bag was 
sealed and had maintained its integrity (holes and rips). Also, the DBS card itself was checked 
for folds or rips.  
For the next category drying of the DBS card was examined. The card should not be put in the 
ziplock bag before it was laid to dry for at least half an hour at room temperature in a non-humid 
environment avoiding direct sunlight. The inside of the zip lock bag and the outer surface of the 
desiccant sachet were inspected for blood stains. DBS cards that have not been dried long 
enough show blood spots of a lighter color.14 
We also assessed whether a 3-, 5- or 8-mm punch could be made without punching the ink from 
the pre-defined circle. Additionally, we examined if the blood spot was consisting of a single 
drop of blood or multiple overlaying drops.  
For the last category, blood spot collection, we examined if the blood spot was collected 
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judging the shape and consistency of the blood spot. We also looked for the presence of a light 
ring around the blood spot, which can result from squeezing the blood from the finger.  
For each category, a series of questions have been included in a checklist (Supplemental Digital 
Content 1, http://links.lww.com/TDM/A345). The DBS cards were accepted for analysis if at 
least two blood spots complied with all quality requirements. Two spots will enable a second 
analysis if something went wrong during sample processing, to confirm the results from the first 
DBS and to allow different sample preparations to be performed for different assays.16   
The checklist was filled in for all DBS cards by two independent DBS experts: MAZ and HV. 
Disagreements were solved by consensus. If the integr ty of the DBS materials was compromised 
or if the drying time was disputable, all four dried blood spots were rejected for analysis. For the 
other two categories, the dried blood spots were scored individually.  
 
Results 
In total 464 DBS cards with four blood spots from four countries were assessed; 117 from 
Bangladesh, 90 from Belarus, 129 from Indonesia and 128 from Paraguay. The amount of blood 
spots that could be analyzed based on punch size per country is shown in Figure 1. Rejection rate 
of the dried blood spots ranged from 13% for Indonesia, 20% for Paraguay, 37% for Belarus to 
52% for Bangladesh. Overall, 46% of all dried blood spots could not be used according to the 
predefined criteria for analysis.  
Most dried blood spots could be punched with an 8mm puncher. This was not the case for the 
blood spots from Belarus. Only 5% of the blood spot were of sufficient size to be punched with 
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In Figure 2, the amount of dried blood spots that were rejected based on four categories is 
shown. DBS cards could not be analyzed in 3% of the 464 cases because of the integrity of the 
materials. Only for the DBS cards from Indonesia, this did not pose a problem. In Indonesia, 
different bags, foil barrier ziplock bags (Whatman, 10534321, GE Healthcare, Little Chalfont, 
United Kingdom) were used instead of the provided plastic zip lock bags. As can be seen in 
Table 1, the biggest issues were due to the plastic bag being open or a missing sachet with 
desiccant. On six DBS cards from Indonesia, a fungus, typed as Aspergillus species, was present. 
Also, the bags from Indonesia contained three DBS cards, only separated by filter papers, 
whereas there should only be one card included per bag. 
The second most important reason for the rejection of dried blood spots was insufficient drying 
time before placing the DBS cards in the zip lock bag. As can be seen from Table 1 and Figure 2, 
this problem was most apparent for the dried blood spots from Bangladesh and Indonesia. 
The biggest cause of rejection was inaccurate blood sp t collection. The DBS cards were mostly 
rejected because of contamination of the dried blood spots, caused by touching the card with 
either a finger or a capillary. The latter could be recognized by small round circles on the filter 
paper. 15% of the dried blood spots from Bangladesh were rejected for touching of the card, 
however an additional problem here was the formation of light rings. This eventually caused 
58% of the blood spots from Bangladesh to be rejectd. For the blood spots from Indonesia, the 
main issue was that 13% of the spots consisted of multiple overlaying drops of blood. Besides 
contamination, blood spot volume was an important reason for rejection in Belarus and Indonesia 
(Figure 2). This low blood volume caused the blood to not soak through the filter paper of the 
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Keeping all criteria in mind, an average of 65% of the DBS cards could be used. For Bangladesh 
this was only 40%, for Belarus 59%, for Indonesia 80% and for Paraguay 77% (Figure 3).  
 
Discussion 
Ultimately, the goal is to implement DBS sampling for TDM of anti-TB drugs, to provide a more 
patient friendly way of sampling in remote settings. DBS sampling can also be used in other 
infectious diseases such as HIV, for which not only plasma-concentrations of antiretroviral drugs 
can be determined with DBS, but also viral load.17 Unfortunately, 46% (859/1856) of the spots in 
our study were rejected based on strict criteria, le ding to an average of 65% of DBS cards that 
could be used. The high rejection rate of samples in our study showed that DBS sampling would 
require more training to produce bloods spots of sufficient quality to be analyzed. This confirms 
the study of Hoogtanders et al. which showed that dried blood spots of sufficient quality for 
analysis could not be obtained with the first method, which is letting the blood drop fall directly 
onto the DBS card, without appropriate training.7,18 This manuscript can help guide healthcare 
workers and researchers to collect dried blood spots of sufficient quality.  
We found that the currently used plastic zip lock bags were not of sufficient quality to protect the 
DBS card from damage, with around 3% of the bags being torn and 4% being open or missing a 
desiccant sachet. The reason for an open ziplock ba, next to opening during transport, could 
also be because they are difficult to close. In Indonesia, different bags were used, which were of 
thicker material. These light protected seal bags did not have any problems as far as opening or 
ripping and could therefore be a better option. A fungus was found on six DBS cards, likely 
caused by contamination of the DBS cards or filter papers dividing the DBS cards, since the 
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itself aided the growth of the fungus. If this is not the case, light protected biohazard seal bags 
are preferred over the currently used plastic ziplock bags. A study by Winter and colleagues 
showed that the analysis results were affected by many contaminants, i.e. feces, disinfectants and 
urine.19 Showing the need for hygiene when performing DBS sampling.  
We also assessed whether punches could be obtained w thout ink from the pre-marked circle. As 
it is not known what influence the ink has on the outc me of the analysis, we have decided to 
reject blood spots that could only be obtained with ink. This was only the case for blood spots 
that could be obtained with an 8mm puncher, therefore it had no influence on the amount of 
blood spots that could ultimately be analyzed.  
Drying conditions was shown to be one of the most important reasons for the rejection of 
samples from Bangladesh, Paraguay and Indonesia. Light rings were also more common in these 
countries, for example for Bangladesh, 45% of the blood spots needed to be rejected because of 
this (Table 1). Because the light rings were more cmmon in these countries, it is more likely 
that a high humidity is the cause of the light rings instead of squeezing of the finger. A high 
humidity requires a longer drying time.20 It could also be that the DBS cards were humid before 
use, because the DBS cards were not stored in a plastic ziplock bag with a desiccant sachet 
before use and were therefore not protected against humid conditions.21 In order to prevent this 
from happening, DBS sampling should be performed in a temperature and humidity controlled 
environment. DBS sampling is not a viable option in remote settings with high humidity or home 
sampling. An alternative could be to store the DBS cards in a box or package with desiccant 
sachets. In such an environment, storage of the coll cted sample can also be done in the box. It 
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DBS sampling can be difficult in case of callous skin. Callous skin is difficult to penetrate with 
the lancet causing issues with obtaining enough blood f r the DBS sampling. This was seen for 
blood spots from Belarus, as the blood spots were too small. Use of another type of lancet or an 
alternative sampling position compared to the finger, i. . the ear lobe, could solve this problem. 
A study by Martial et al. showed that DBS sampling would not only be more patient friendly, but 
also cost-effective, if it could be performed at home.23 Without practical training it is shown to 
be difficult to obtain a blood spot from which the drug concentration can be accurately 
determined. As TDM for the optimization of TB treatment will likely be performed using 2-4 
rounds of TDM, 24,25 it will be easier and more cost effective to train healthcare workers instead 
of patients. Because TB patients visit the public health service regularly, the DBS sampling 
could be performed during a scheduled visit. Based on the results from this study, the 
instructions need to be amended. Instructions could also be made available in native languages in 
order to overcome interpretation issues.  
Conclusion 
More practical training is needed to adequately perform DBS sampling. Compliance with storage 
and shipment conditions is important to have the DBS sample arrive in the lab and pass quality 
checks.  
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Figure Legends 
Figure 1. The dried blood spots per country and per punch size. This figure shows how 
many dried blood spots could be punched and with which minimum size. If a dried blood spot 
could be punched with an 8 mm puncher, then it is part of the percentage that could be punched 
with an 8mm puncher and not with a 5 or 3 mm puncher. 
Figure 2. Percentage of dried blood spots that were rejected, divided in four categories.  
The results are shown for the four categories separately and not as overall results. One dried 
blood spot can be part of multiple categories.  
Figure 3. Percentage of DBS cards that could be used per country. The percentage of DBS 
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Table 1. Percentage of DBS cards that could be used per question from the checklist 
 
Category Question Bangladesh, 
% 
N = 117 DBS 
cards with 4 
blood spots 
Belarus, % 
N = 90 DBS 
cards with 4 
blood spots 
Indonesia, % 
N = 129 DBS 
cards with 4 
blood spots 
Paraguay, % 
N = 128 DBS 
cards with 4 
blood spots 
Overall, % 





95 87 100 98 96 
Bag in tact 97 96 100 95 97 
DBS card 
in tact 
98 100 100 98 99 
Appropriate 









99 99 100 100 100 
Blood volume One drop 
of blood 























55 100 92 92 73 
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